Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

BROOKLYN IMMUNOTHERAPEUTICS, INC.

(BTX)
  Report
SummaryQuotesChartsNewsCalendarCompanyFinancialsConsensusRevisions 
 SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news
Most relevant news about BROOKLYN IMMUNOTHERAPEUTICS, INC.
01/20Brooklyn ImmunoTherapeutics Welcomes Erin S. Enright and Heather B. Redman to Its Board..
GL
01/20Brooklyn ImmunoTherapeutics, Inc. Appoints Erin S. Enright and Heather B. Redman to its..
CI
01/13Brooklyn ImmunoTherapeutics Provides Update on Regenerative Medicine Intellectual Prope..
AQ
2021Cantor Fitzgerald Starts Brooklyn ImmunoTherapeutics at Overweight With $9 Price Target
MT
2021Brooklyn Immunotherapeutics, Inc. Announces Resignation of Luba Greenwood as Director E..
CI
2021Brooklyn ImmunoTherapeutics Added to ICE Biotechnology Index
AQ
2021BROOKLYN IMMUNOTHERAPEUTICS, INC.(NA : BTX) added to NASDAQ Biotechnology Index
CI
2021Brooklyn ImmunoTherapeutics Added toáICE Biotechnology Index
AQ
2021Brooklyn ImmunoTherapeutics Named to Nasdaq Biotechnology Index
AQ
2021Brooklyn ImmunoTherapeutics to Present at Two Upcoming December Conferences
AQ
2021Brooklyn ImmunoTherapeutics Welcomes Susan McClatchey as Vice President and Head of Qua..
GL
2021Brooklyn ImmunoTherapeutics, Inc. Appoints Susan McClatchey as Head of Quality
CI
2021Brooklyn ImmunoTherapeutics Plans Secondary Offering Of 6.28 Million Shares
MT
2021Brooklyn ImmunoTherapeutics Announces Filing of Registration Statement for Proposed Sec..
AQ
2021Earnings Flash (BTX) BROOKLYN IMMUNOTHERAPEUTICS LLC Posts Q3 Loss $-1.70
MT
More most relevant news
All news about BROOKLYN IMMUNOTHERAPEUTICS, INC.
01/20BROOKLYN IMMUNOTHERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
01/20Brooklyn ImmunoTherapeutics Welcomes Erin S. Enright and Heather B. Redman to Its Board..
GL
01/20Brooklyn ImmunoTherapeutics, Inc. Appoints Erin S. Enright and Heather B. Redman to its..
CI
01/13Brooklyn ImmunoTherapeutics Provides Update on Regenerative Medicine Intellectual Prope..
AQ
01/05BROOKLYN IMMUNOTHERAPEUTICS, INC. : Costs Associated with Exit or Disposal Activities (for..
AQ
2021Cantor Fitzgerald Starts Brooklyn ImmunoTherapeutics at Overweight With $9 Price Target
MT
2021BROOKLYN IMMUNOTHERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
2021Brooklyn Immunotherapeutics, Inc. Announces Resignation of Luba Greenwood as Director E..
CI
2021Brooklyn ImmunoTherapeutics Added to ICE Biotechnology Index
AQ
2021BROOKLYN IMMUNOTHERAPEUTICS, INC.(NA : BTX) added to NASDAQ Biotechnology Index
CI
More news
News in other languages on BROOKLYN IMMUNOTHERAPEUTICS, INC.
01/20Brooklyn ImmunoTherapeutics, Inc. nomme Erin S. Enright et Heather B. Redman à son cons..
2021Brooklyn Immunotherapeutics, Inc. annonce que Luba Greenwood a informé le conseil d'adm..
2021Brooklyn ImmunoTherapeutics propose un placement secondaire de 6,28 millions d'actions
2021Brooklyn Immunotherapeutics transfère la cotation de ses actions du NYSE American au Na..
2021Brooklyn ImmunoTherapeutics nomme Roger Sidhu directeur médical en chef
2021Les ventes d'initiés à Brooklyn Immunotherapeutics (BTX) sont importantes.
2021Brooklyn ImmunoTherapeutics signe une lettre d'intention non contraignante pour rachete..
2021Brooklyn ImmunoTherapeutics fait son entrée dans l'indice Russell 3000
2021Brooklyn ImmunoTherapeutics crée un centre dans le Massachusetts pour développer l'édit..
2021Brooklyn Immunotherapeutics vendra jusqu'à 40 millions de dollars d'actions ordinaires ..
More news
Analyst Recommendations on BROOKLYN IMMUNOTHERAPEUTICS, INC.
2021Cantor Fitzgerald Starts Brooklyn ImmunoTherapeutics at Overweight With $9 Price Target
MT
2021BROOKLYN IMMUNOTHERAPEUTICS : Maxim Starts Brooklyn ImmunoTherapeutics at Buy with $20 Pri..
MT
More recommendations
Press releases
01/20BROOKLYN IMMUNOTHERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
01/20Brooklyn ImmunoTherapeutics Welcomes Erin S. Enright and Heather B. Redman to Its Board..
GL
01/13Brooklyn ImmunoTherapeutics Provides Update on Regenerative Medicine Intellectual Prope..
AQ
01/05BROOKLYN IMMUNOTHERAPEUTICS, INC. : Costs Associated with Exit or Disposal Activities (for..
AQ
2021BROOKLYN IMMUNOTHERAPEUTICS, INC. : Change in Directors or Principal Officers (form 8-K)
AQ
More press releases